In this episode of Denatured, Dr. Peter Marks M.D., PhD. gives his thoughts on the future of cell and gene therapies. He speaks candidly about opportunities and realities, manufacturing and its role in efficacy and the CGT runway. 
 
Dr. Marks was keynote speaker at the <a href="https://genscript-global-biotech-forum.cventevents.com/event/0027fbb0-b171-4f52-bcd9-ba57c357928e/home?RefId=GSLI&rt=mNTwbuhvm0e50fAXhWDPOQ" target="_blank" rel="ugc noopener noreferrer">GenScript Biotech Forum</a> in San Francisco this week.
 
Host
<a href="https://www.linkedin.com/in/lorielliskatz/" target="_blank" rel="ugc noopener noreferrer">⁠Lori Ellis⁠</a>, Head of Insights, BioSpace
 
Guest
<a href="https://www.fda.gov/about-fda/fda-organization/peter-marks" target="_blank" rel="ugc noopener noreferrer">⁠Peter Marks M.D., PhD.⁠</a>, Director, Center for Biologics Evaluation and Research (CBER)

Bonus: Q4 2024 Job Market Update

Unravel the business of science with BioSpace. We dive into biopharma's top stories and biggest challenges, whether it’s layoffs, pipeline shake-ups, acquisitions, new FDA approvals or how to regulate AI in drug development.